IntroductionStatin belongs to a medication class of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) inhibitor. It is the most significant drug used for lipid-lowering and cardiovascular disease prevention1. A wide range of statin myopathy has been reported including myalgia, myopathy, myositis, or rhabdomyolysis. Statin-induced immune-mediated necrotizing myopathy (IMNM) is a relatively rare side effect with an incidence of 2 or 3 of every 100,000 patients taking statins2. Many different findings help differentiate toxic non-inflammatory effects from immune-mediated myopathy due to statins1. We report a case of statin-induced IMNM with oropharyngeal involvement.